Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to -$670000.0.

  • ImmunoTech's Gains from Investment Securities fell 12782.76% to -$670000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$749000.0, marking a year-over-year decrease of 13110.88%. This contributed to the annual value of $2.8 million for FY2024, which is 1553412.22% up from last year.
  • ImmunoTech's Gains from Investment Securities amounted to -$670000.0 in Q3 2025, which was down 12782.76% from -$17000.0 recorded in Q2 2025.
  • In the past 5 years, ImmunoTech's Gains from Investment Securities registered a high of $2.8 million during Q4 2024, and its lowest value of -$670000.0 during Q3 2025.
  • Over the past 3 years, ImmunoTech's median Gains from Investment Securities value was $2000.0 (recorded in 2023), while the average stood at $644546.0.
  • As far as peak fluctuations go, ImmunoTech's Gains from Investment Securities soared by 14060710.0% in 2024, and later plummeted by 12782.76% in 2025.
  • Quarter analysis of 3 years shows ImmunoTech's Gains from Investment Securities stood at $2000.0 in 2023, then skyrocketed by 140607.1% to $2.8 million in 2024, then plummeted by 123.81% to -$670000.0 in 2025.
  • Its Gains from Investment Securities was -$670000.0 in Q3 2025, compared to -$17000.0 in Q2 2025 and -$64000.0 in Q1 2025.